» Articles » PMID: 39457572

An Updated Comprehensive Review on Diseases Associated with Nephrotic Syndromes

Overview
Journal Biomedicines
Date 2024 Oct 26
PMID 39457572
Authors
Affiliations
Soon will be listed here.
Abstract

There have been exciting advances in our knowledge of primary glomerular diseases and nephrotic syndromes in recent years. Beyond the histological pattern from renal biopsy, more precise phenotyping of the diseases and the use of modern nephrogenetics helps to improve treatment decisions and sometimes also avoid unnecessary exposure to potentially toxic immunosuppression. New biomarkers have led to easier and more accurate diagnoses and more targeted therapeutic decisions. The treatment landscape is becoming wider with a pipeline of promising new therapeutic agents with more sophisticated approaches. This review focuses on all aspects of entities that are associated with nephrotic syndromes with updated information on recent advances in each field. This includes podocytopathies (focal segmental glomerulosclerosis and minimal-change disease), membranous nephropathy, membranoproliferative glomerulonephritis, IgA nephropathy, fibrillary glomerulonephritis, amyloidosis, and monoclonal gammopathy of renal significance in the context of the nephrotic syndrome, but also renal involvement in systemic diseases, diabetic nephropathy, and drugs that are associated with nephrotic syndromes.

References
1.
Ruilope L, Pitt B, Anker S, Rossing P, Kovesdy C, Pecoits-Filho R . Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol Dial Transplant. 2022; 38(2):372-383. PMC: 9923706. DOI: 10.1093/ndt/gfac157. View

2.
Pickering M, DAgati V, Nester C, Smith R, Haas M, Appel G . C3 glomerulopathy: consensus report. Kidney Int. 2013; 84(6):1079-89. PMC: 3842953. DOI: 10.1038/ki.2013.377. View

3.
Floege J, Daha M . IgA nephropathy: new insights into the role of complement. Kidney Int. 2018; 94(1):16-18. DOI: 10.1016/j.kint.2018.03.009. View

4.
Clark M, Trotter K, Chang A . The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis. Semin Nephrol. 2015; 35(5):455-64. PMC: 4653081. DOI: 10.1016/j.semnephrol.2015.08.007. View

5.
Lafayette R, Kristensen J, Stone A, Floege J, Tesar V, Trimarchi H . Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023; 402(10405):859-870. DOI: 10.1016/S0140-6736(23)01554-4. View